These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23735235)

  • 21. Rasagiline for the treatment of Parkinson's disease: an update.
    Stocchi F; Fossati C; Torti M
    Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Elmer LW
    Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rasagiline treatment effects on parkinsonian tremor.
    Lew MF
    Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
    Zhang L; Zhang Z; Chen Y; Qin X; Zhou H; Zhang C; Sun H; Tang R; Zheng J; Yi L; Deng L; Li J
    Int J Neuropsychopharmacol; 2013 Aug; 16(7):1529-37. PubMed ID: 23551956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
    Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
    Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasagiline: a guide to its use in Parkinson's disease.
    Keating GM; Lyseng-Williamson KA; Hoy SM
    CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
    Jiang DQ; Wang HK; Wang Y; Li MX; Jiang LL; Wang Y
    Neurol Sci; 2020 Jan; 41(1):101-109. PubMed ID: 31446579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
    Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
    Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Hauser RA; Lew MF; Hurtig HI; Ondo WG; Wojcieszek J; Fitzer-Attas CJ;
    Mov Disord; 2009 Mar; 24(4):564-73. PubMed ID: 19086083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
    Solís-García del Pozo J; Mínguez-Mínguez S; de Groot PW; Jordán J
    Expert Opin Drug Saf; 2013 Jul; 12(4):479-86. PubMed ID: 23634791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Olanow CW; Kieburtz K; Leinonen M; Elmer L; Giladi N; Hauser RA; Klepiskaya OS; Kreitzman DL; Lew MF; Russell DS; Kadosh S; Litman P; Friedman H; Linvah N; The P B Study Group F
    Mov Disord; 2017 May; 32(5):783-789. PubMed ID: 28370340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    McCormack PL
    CNS Drugs; 2014 Nov; 28(11):1083-97. PubMed ID: 25322951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rasagiline in Parkinson's disease].
    Linazasoro G
    Neurologia; 2008 May; 23(4):238-45. PubMed ID: 18307054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
    Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
    N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
    Stocchi F
    Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):299-308. PubMed ID: 30689042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.